Printer Friendly

Pharming receives shareholders' approval for share issue.

M2 PHARMA-February 3, 2012-Pharming receives shareholders' approval for share issue(C)2012 M2 COMMUNICATIONS

3 February 2012 - Dutch biotech Pharming Group NV (AMS:PHARM) said today its shareholders had authorised at an extraordinary meeting the issue of 255m new shares.

The company's share capital will thus rise to 805m shares.

Pharming also said it had presented to the shareholders alternatives to deal with its negative equity situation. The company pointed it expects a milestone payment of up to USD15m (EUR11.5m) from successful finalisation of a US study.

Pharming announced last December a negative equity capital referring to among others changes needed to comply with the IFRS accounting requirements.

(USD1 = EUR0.764)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 3, 2012
Words:123
Previous Article:FDA lifts partial clinical hold on Idenix's HCV nucleotide inhibitor IDX184.
Next Article:Schlecker has no problems with distributors despite insolvency.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters